Prognostic value of the right ventricular ejection fraction using three-dimensional echocardiography: Systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
01
2023
accepted:
15
06
2023
medline:
10
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Three-dimensional echocardiography (3DE) is a robust method for measuring the right ventricular (RV) ejection fraction (EF), which is closely associated with outcomes. We performed a systematic review and meta-analysis (1) to examine the prognostic value of RVEF and (2) to compare its prognostic value with that of left ventricular (LV) EF and LV global longitudinal strain (GLS). We also performed individual patient data analysis to validate the results. We searched articles reporting the prognostic value of RVEF. Hazard ratios (HR) were re-scaled using the within-study standard deviation (SD). To compare predictive values of RVEF and LVEF or LVGLS, the ratio of HR related to a 1-SD reduction of RVEF versus LVEF or LVGLS was calculated. Pooled HR of RVEF and pooled ratio of HR were analyzed in a random-effects model. Fifteen articles with 3,228 subjects were included. Pooled HR of a 1-SD reduction of RVEF was 2.54 (95% confidence interval (CI): 2.15-3.00). In subgroup analysis, RVEF was significantly associated with outcome in pulmonary arterial hypertension (PAH) (HR: 2.79, 95% CI: 2.04-3.82) and cardiovascular (CV) diseases (HR: 2.23, 95%CI: 1.76-2.83). In studies reporting HRs for both RVEF and LVEF or RVEF and LVGLS in the same cohort, RVEF had 1.8-fold greater prognostic power per 1-SD reduction than LVEF (ratio of HR: 1.81, 95%CI: 1.20-2.71), but had predictive value similar to that of LVGLS (ratio of HR: 1.10, 95%CI: 0.91-1.31) and to LVEF in patients with reduced LVEF (ratio of HR: 1.34, 95%CI: 0.94-1.91). In individual patient data analysis (n = 1,142), RVEF < 45% was significantly associated with worse CV outcome (HR: 4.95, 95% CI: 3.66-6.70), even in patients with reduced or preserved LVEF. The findings of this meta-analysis highlight and support the use of RVEF assessed by 3DE to predict CV outcomes in routine clinical practice in patients with CV diseases and in those with PAH.
Identifiants
pubmed: 37418388
doi: 10.1371/journal.pone.0287924
pii: PONE-D-23-01475
pmc: PMC10328342
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0287924Informations de copyright
Copyright: © 2023 Kitano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Heart J Cardiovasc Imaging. 2020 Jan 1;21(1):10-21
pubmed: 31539046
Circ Cardiovasc Imaging. 2021 Mar;14(3):e011337
pubmed: 33722059
J Am Coll Cardiol. 2007 Feb 27;49(8):855-62
pubmed: 17320743
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
JACC Cardiovasc Imaging. 2020 Jun;13(6):1395-1405
pubmed: 31954639
J Epidemiol Community Health. 1998 Jun;52(6):377-84
pubmed: 9764259
Circ Cardiovasc Imaging. 2017 Feb;10(2):
pubmed: 28174197
J Am Soc Echocardiogr. 2023 Jun;36(6):624-633.e8
pubmed: 36773817
J Am Soc Echocardiogr. 2014 Jul;27(7):726-32
pubmed: 24679740
Nat Rev Cardiol. 2010 Oct;7(10):551-63
pubmed: 20697412
Eur Heart J Cardiovasc Imaging. 2018 Apr 1;19(4):450-458
pubmed: 28637308
Int J Cardiol. 2022 Dec 01;368:94-103
pubmed: 35961612
J Am Soc Echocardiogr. 2015 Oct;28(10):1222-31
pubmed: 26237996
Circ Cardiovasc Imaging. 2020 Jul;13(7):e010568
pubmed: 32673506
Front Cardiovasc Med. 2021 Jul 02;8:690606
pubmed: 34277739
Front Cardiovasc Med. 2021 Feb 09;8:641088
pubmed: 33634177
JACC Cardiovasc Imaging. 2021 May;14(5):931-942
pubmed: 33008758
Oncotarget. 2016 Dec 27;7(52):86781-86790
pubmed: 27893420
Eur Heart J Cardiovasc Imaging. 2020 Jul 1;21(7):787-795
pubmed: 31549722
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Circ Cardiovasc Imaging. 2021 Oct;14(10):e012774
pubmed: 34587749
Heart. 2014 Nov;100(21):1673-80
pubmed: 24860005
Front Cardiovasc Med. 2021 Dec 13;8:795016
pubmed: 34966801
J Am Soc Echocardiogr. 2019 Nov;32(11):1407-1415.e3
pubmed: 31400846
J Am Soc Echocardiogr. 2020 Aug;33(8):985-994.e1
pubmed: 32532643
Front Cardiovasc Med. 2021 Jun 30;8:694365
pubmed: 34277743
Front Cardiovasc Med. 2022 Feb 25;9:837584
pubmed: 35282348
Circ Cardiovasc Imaging. 2014 Jan;7(1):190-7
pubmed: 24449548
J Am Soc Echocardiogr. 2022 Jun;35(6):600-608.e3
pubmed: 35158050
Int J Cardiovasc Imaging. 2021 Nov;37(11):3233-3244
pubmed: 34165699